Join

Compare · ANPC vs ILMN

ANPC vs ILMN

Side-by-side comparison of AnPac Bio-Medical Science Co. Ltd. (ANPC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ANPC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ILMN is the larger of the two at $51.89B, about 1374.5x ANPC ($37.7M).
  • ILMN has hit the wire 5 times in the past 4 weeks while ANPC has been quiet.
  • ILMN has more recent analyst coverage (25 ratings vs 0 for ANPC).
MetricANPCILMN
Company
AnPac Bio-Medical Science Co. Ltd.
Illumina Inc.
Price
$4.53-7.74%
$127.93+2.01%
Market cap
$37.7M
$51.89B
1M return
-
+1.37%
1Y return
-
+65.69%
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NASDAQ
IPO
2020
2000
News (4w)
0
5
Recent ratings
0
25
ANPC

AnPac Bio-Medical Science Co. Ltd.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China. It offers cancer differentiation analysis devices and physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.

ILMN

Illumina Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Latest ANPC

Latest ILMN